01:10 PM EST, 12/03/2025 (MT Newswires) -- (Updates with the latest stock price movement in the headline and the first paragraph.)

Capricor Therapeutics ( CAPR ) shares rose 375% in recent Wednesday trading after the company said that a pivotal late-stage trial evaluating its investigational cell therapy Deramiocel to treat boys and young men with Duchenne muscular dystrophy met both its primary endpoint and a key secondary endpoint.

Capricor said it expects the study's results to address the clinical issues raised in a complete response letter received from the US Food and Drug Administration earlier this year. It also said Deramiocel had a favorable safety and tolerability profile, which was consistent with prior clinical experiences.

The trial "delivered strong and definitive evidence that Deramiocel can meaningfully improve the course of Duchenne muscular dystrophy, demonstrating statistically significant improvements in both skeletal and cardiac function," the company quoted its chief executive officer, Linda Marban, as saying.

Price: 30.34, Change: +23.98, Percent Change: +377.03